The Combination of Goodpasture syndrome and granulomatosis with polyangiitis
- Authors: Vetsheva M.S1, Podkorytova O.L2, Artyukhina L.Y.2, Loss K.E2, Lysenko M.A2
-
Affiliations:
- Sechenov First Moscow State Medical University
- City Clinical Hospital № 52 of the Moscow Healthcare Department
- Issue: Vol 12, No 2 (2020)
- Pages: 52-60
- Section: Articles
- URL: https://journals.eco-vector.com/2075-3594/article/view/273348
- DOI: https://doi.org/10.18565/nephrology.2020.2.52-60
- ID: 273348
Cite item
Abstract
Full Text
About the authors
M. S Vetsheva
Sechenov First Moscow State Medical UniversityDoctor of Medical Sciences, Professor at the Department of Anesthesiology and Emergency Medicine Moscow, Russia
O. L Podkorytova
City Clinical Hospital № 52 of the Moscow Healthcare Department
Email: o-podkorytova@yandex.ru
PhD in Medical Sciences, Head of the Resuscitation and Intensive Care Unit №2 (for nephrological patients) Moscow, Russia
L. Yu Artyukhina
City Clinical Hospital № 52 of the Moscow Healthcare DepartmentPhD in Medical Sciences, Head ofthe Nephrology Department № 1 Moscow, Russia
K. E Loss
City Clinical Hospital № 52 of the Moscow Healthcare DepartmentAnesthesiologist-Intensivist, Resuscitation and Intensive Care Unit № 2 (for nephrological patients) Moscow, Russia
M. A Lysenko
City Clinical Hospital № 52 of the Moscow Healthcare DepartmentDoctor of Medical Sciences, Professor, Chief Physician Moscow, Russia
References
- Мухин Н.А. Синдром Гудпасчера: патогенез, диагностика, лечение. Фарматека. 2011;18:8-14
- Naidoo S, Waller S. Anti-GBM antibodies co-exist with MPO-ANCA in a 4-year-old girl with acute renal failure. Pediatr. Nephrol. 2009;24(1):215-216.
- Лечение гломерулонефрита, обусловленного антителами к гломерулярной базальной мембране. Клинические практические рекомендации KDIGO по лечению гломерулонефритов. Нефрология и диализ. 2014;136-140.
- Hellmark T., Segelmark M. Diagnosis and classification of Goodpasture’s disease (anti-GBM). J. Autoimmun. 2014;48-9:108-112
- Yang R., Cui Z., Zhao J., Zhao M.H. The role of HLA-DRB1 alleles on susceptibility of Chinese patients with anti-GBM disease. Clin. Immunol. 2009;133(2):245-250.
- Bayat A., Kamperis K, Herlin T. Characteristics and outcome of Goodpasture’s disease in children. Clin. Rheumatol. 2012;31(12): 1745-1751.
- Greco A., et al. Goodpasture’s syndrome: A clinical update. Autoimmun. Rev. 2014;14(3):246-253.
- Persson U, Hertz J.M., Carlsson M., et al. Patients with Goodpasture’s disease have two normal COL4A3 alleles encoding the NC1 domain of the type IV collagen alpha 3 chain. Nephrol. Dial. Transplant. 2004;19:2030-2035.
- Hudson B.G., Tryggvason K., Sundaramoorthy M., Neil son E.G. Alport’s syndrome, Goodpasture’s syndrome, and type IV collagen. N. Engl. J. Med. 2003;348:2543-2556.
- Zou J., Henderson L., Thomas V., et al. Presentation of the Goodpasture autoantigen requires proteolytic unlocking steps that destroy prominent T cell epitopes. J. Am. Soc. Nephrol. 2007;18(3):771-779.
- Cui Z., Zhao M.-H. Advances in human antiglomerular membrane disease. Nat. Rev. Nephr. 2011;7:(12):697- 705.
- Rutgers A., Meyers K.E., Canziani G., et al. High affinity of anti-GBM antibodies from Goodpasture and transplanted Alport patients.to alpha 3 (IV) NC1 collagen. Kidney Int. 2000;58:115-122.
- Ohlsson S., Herlitz H., Selga D., et al. Circulating Anti-Glomerular Basement Membrane Antibodies with Predominance of Subclass IgG4 and False-Negative Immunoassay Test Results in Anti-Glomerular Basement Membrane Disease. Am. J. Kidney Dis. 2014;63(2):289-293.
- Salama A.D., Chaudhry A.N., Ryan J.J., et al. In Goodpasture’s disease, CD4(+) T cells escape thymic deletion and are reactive with the autoantigen alpha3 (IV) NC1. J. Am. Soc. Nephrol 2001;12:1908-1915.
- Silvarino R., Noboa O., Cervera R. Anti-glomerular basement membrane antibodies. Israel Med. Associat. J. 2014;16(11):727-732.
- Meyera D., Colesb A., Oyuelac P., et al. Case report of anti-glomerular basement membrane disease following alemtuzumab treatment of relapsing-remitting multiple sclerosis. Mult. Scleros. Relat. Disord. 2013;2(1):60-63.
- Dean E.G., Wilson G.R., Li M., et al. Experimental autoimmune Goodpasture’s disease: a pathogenetic role for both effector cells and antibody in injury. Kidney Int. 2005;67:566-575.
- Okada H., Moriwaki K., Kalluri R., et al. Inhibition of monocyte hemoattractant protein-1 expression in tubular epithelium attenuates tubulointerstitial alteration in rat Goodpasture syndrome. Kidney Int. 2000;57:927-936.
- Kidney Disease: Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group. KDIGO Clinical Practice Guideline for Glomerulonephritis. Kidney Int. 2012;Suppl.(2):139-274.
- Kuroda T., Yoshida Y, Kamiie J, et al. Expression of MMP-9 in mesangial cells and its changes in anti-GBM glomerulonephritis in WKY rats. Clin Exp Nephrol 2004;8(3):206-215.
- Мухин Н.А. Синдром Гудпасчера. В кн. Нефрология (рук-во для врачей). М., 2000. [Mukhin N.A. Goodpasture Syndrome. V kn. Nefrologiya (ruk-vo dlya vrachey). M., 2000. (In Russ.)].
- Salama A.D., Levy J.B., Lightstone L., Pusey C.D. Goodpasture’s disease. Lancet. 2001;358:917-920.
- Touzot M., Poisson J., Faguer S., et al. Rituximab in anti-GBM disease: A retrospective study of 8patients. J. Autoimmun. 2015;60:74-79.
- Laczika K., Knapp S., Derfler K., et al. Immunoadsorption in Goodpasture’s syndrome. Am. J. Kidney Dis. 2000;36:392-25.
- Baumgartner I., Gmur J., Fontana A., et al. Recovery from life threatening pulmonary hemorrhage in Goodpasture’s syndrome after plasmapheresis and subsequent pulse dose cyclosphosphamide. Clin. Nephrol. 1995;43:68-70.
- Garcia-Canton C., Toledo A., Palomar R., et al. Goodpasture’s syndrome treated with mycofenolat mofetil. Nephrol. Dial. Transplant. 2000;15:920-922.
- Takeda S., Takahashi M., Sado Y., et al. Prevention of glomerular crescent formation in glomerulonephritis by mycophenolate mofetil in rats. Nephrol. Dial. Transplant. 2004;19(9):2228-2236.
- Huang L., Garcia G., Lou Y., et al. Antiinflammatory and renal protective actions of stanniocalcin-1 in a model of anti-glomerular basement membrane glomerulonephritis. Am. J. Pathol. 2009;174(4):1368-1378.
- Asgeirsdottir S.A., Zwiers P.J., Morselt H.W., et al. Inhibition of proinflammatory genes in anti-GBM glomerulonephritis by targeted dexamethasoneloaded AbEsel liposomes. Am. J. Physiol. Renal. Physiol. 2008;294(3):554-561.
- Garcia G.E., Truong L.D., Li P., et al. Inhibition of CXCL16 attenuates inflammatory and progressive phases of anti-glomerular basement membrane antibody-associated glomerulonephritis. Am. J. Pathol. 2007;170(5):1485-1496.
- Leh S., Vaagnes O., Margolin S.B., et al. Pirfenidone and candesartan ameliorate morphological damage in mild chronic anti-GBM nephritis in rats. Nephrol. Dial. Transplant. 2005;20(1):71-82.
- Bayat A., Kamperis K., Herlin T. Characteristics and outcome of Goodpasture’s disease in children. Clin. Rheumatol. 2012;31:12:1745-1751.
- West S.C., Arulkumaran N., Ind P.W., et al. Pulmonary-renal syndrome: a life threatening but treatable condition. Postgrad. Med. J. 2013;89:1051: 274-283.
- Watts R.A. Epidemiology of vasculitis. R.A. Watts, D.G.I. Scott. Vasculitis. 2nd ed. Oxford: Oxford University Press. 2008. С. 7-22.
- Ntatsaki E. Epidemiology of ANCA-associated vasculitis. E. Ntatsaki, R.A. Watts, D.G. Scott. Rheum. Dis. Clin. North Am. 2010;565:447-461.
- Savage C.O. Pathogenesis of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis/C.O. Savage. Clin. Exp. Immunol. 2011;164:23-26.
- Stegeman C.A., Cohen Tervaert J.W., Sluiter W.J. et al. Association of nasal carriage of Staphylococcus aureus and higher relapse in Wegener’s granulomatosis. Ann. Intern. Med. 1994;120:12-17.
- Popa E.R., Stegeman C.A., Abdulahad W.H., van der Meer B., Arends J., Manson W.M., Bos N.A., Kallenberg C.G., Tervaert J.W. Staphylococcal toxic-shock-syndrome-toxin-1 as a risk factor for disease relapse in Wegener’s granulomatosis. Rheumatol. (Oxford) 2007;46(6):1029-1033.
- Van der Woude F., Rasmussen N., Lobatto S., et al. Autoantibodies against neutrophils and monocytes: tool for diagnosis and marker of disease activity in Wegener’s granulomatosis. Lancet. 1985;1:425-429.
- Kain R., et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat. Med. 2008;14:1088-1096.
- Roth A.J., et al. Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis. J. Am. Soc. Nephrol. 2012;23:545-555.
- Yates M., Watts R.A., Bajema I.M., et al. EULAR/ERA-EDTA recommendations for the management of ANCA-associated vasculitis. Ann. Rheum. Dis. 2016 Jun 23. pii: annrheumdis-2016-209133. Doi: 10.1136/ annrheumdis-2016-209133.
- Бекетова Т.В. АНЦА-ассоциированный системный васкулит. Нефрология. Национальное руководство. М., 2014. [Beketova T.V. ANTSA-assotsiirovannyy sistemnyy vaskulit. Nefrologiya. Natsional’noye rukovodstvo. M., 2014. (In Russ.)].
- Kallenberg C.G. Pathogenesis of ANCA-associated vasculitis, an update. Clin. Rev. Allergy Immunol. 2011;41(2):224-231.
- Gomez-Puerta J.A., Bosch X. Anti-neutrophil cytoplasmic antibody pathogenesis in small-vessel vasculitis: an update. Am. J. Pathol. 2009;175:1790-1798.
- Falk R.J., Terrell R.S., Charles L.A., Jennette J.C. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc. Natl. Acad. Sci. 1990;87:4115-4119.
- Booth A., Harper L., Hammad T., Bacon P., Griffith M., Levyet J., et al. Prospective study of TNF alpha blockade with infliximab in anti-neutrophil cytoplasmic antibody-associated systemic vasculitis. J. Am. Soc. Nephrol. 2004;820:717-721.
- Shlomchik M.J., Craft J.E., Mamula M.J. From T to B and back again: positive feedback in systemic autoimmune disease. Nat. Rev. Immunol. 2001;200:147-153.
- Voswinkel J, Mueller A., Kraemer J.A., Lamprecht P., Herlyn K., Holl-Ulrich K., Feller A.C., Pitann S., Gause A., Gross W.L. B lymphocyte maturation in Wegener’s granulomatosis: a comparative analysis of VHgenes from endonasal lesions. Ann. Rheum. Dis. 2006;1200:859-64.
- Gross W.L. Immunopathology and newtherapeutic considerations in ANCA-associated vasculitides. Autoimmun. Rev. 2004;120:47-48.
- Harper L, Savage С. Pathogenesis of ANCA-associated systemic vasculitis. J. Pathol. 2000;190:149-159.
- Vital A., Vital C, Viallard J.F., Ragnaud J.M., Canron M.H., Lagueny A. Neuro-muscular biopsy in Churg-Strauss syndrome: 24 cases. J. Neuropathol. Exp. Neurol. 2006;65(2):187-92.
- Berden A.E., Ferrario F, Hagen E.C., Jayne D.R., Jennette J.C., Joh K., Neumann I., Noel L.H., Pusey C.D., Waldherr R., Bruijn J.A., Bajema I.M. Histopathologic lassification of ANCA-associated glomerulonephritis. J. Am. Soc. Nephrol. 2010;21(10):1628-1636.
- KDIGO Clinical Practice Guideline for glomerulonephritis. Kidney Int Suppl 2012; 2:139-274.
- Бекетова Т.В. Перспективы применения ритуксимаба при васкулитах, ассоциированных с антинейтрофильными цитоплазматическими антителами. Научно-практическая ревматология, 2010;4(1):80-90.
- Specks U., Merkel P.A., et al, for the RAVE-ITN Research Grou. Efficacy of Remission-Induction Regimens for ANCA - Associated Vasculitis. N. Engl. J. Med. 2013;369:417-427.
- Бекетова Т.В., Александрова Е.Н., Новоселова Т.М. и др. Российский опыт применения моноклональных антител к В-лимфоцитам (ритуксимаб) при системных васкулитах, ассоциированных с антинейтрофильными цитоплазматическими антителами (предварительные результаты российского регистра НОРМА). Научно-практическая ревматология. 2014;52(2):147-158.
- Hebert L.A., Alvarado A., Rovin B. Rituximab or Azathioprine Maintenance in ANCA-Associated Vasculitis. N. Engl. J. Med. 2015;372:385-387.
- Бекетова Т.В. Европейские (EULAR/ERA-EDTA) рекомендации по диагностике и лечению АНЦА-ассоциированных системных васкулитов. 2016. Научно-практическая ревматология. 2017;55(1):12-16.
- Jayne D.R.W., Gaskin G., Rasmussen N., et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J. Am. Soc. Nephrol. 2007;18:2180-2188.
- Ward D.M. Conventional apheresis therapies: a review. J. Clin. Apher. 2011;26 (5):230-238.
- Gregersen J.W., Kristensen T., Krag S.R., Birn H., Ivarsen P. Early plasma exchange improves outcome in PR3-ANCA-positive renal vasculitis. Clin. Exp. Rheumatol. 2012;30(1 Suppl. 70):39-47.
- Chen Y., Yang L., Li K., et al. Double Filtration Plasmapheresis in the Treatment of Antineutrophil Cytoplasmic Autoantibody Associated Vasculitis with Severe Renal Failure: A Preliminary Study of 15 Patients. Ther. Apher. Dial. 2016; 20(2):183-188.
- Klemmer P.J., Chalermskulrat W., Reif M.S., et al. Plasmapheresis therapy for diffuse alveolar hemorrhage in patients with Small-Vessel vasculitis. Am. J. Kidney Dis. 2003;42:1149-1153.
- Levy J.B., Hammad T., Coulthart A., et al. Clinical features and outcome of patients with both ANCA and anti-GBM antibodies. Kidney Int. 2004;66:1535-1541.